Screener
Wave Life Sciences WVE GB — Effective Income Tax Rate Reconciliation Tax Credits Research
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch.
The source filing: Wave Life Sciences’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:50 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-073472
| Line item | Year Ended December 31, 2025 / Amount | Year Ended December 31, 2025 / Percent |
|---|---|---|
| Other1 | 2,298 | (1.1) |
| UK | ||
| Statutory tax rate difference between the United Kingdom and Singapore | (5,409) | 2.6 |
| Research and development | (1,836) | 0.9 |
| Changes in valuation allowances | 18,742 | (9.2) |
| Other | 59 | — |
| Other Foreign Jurisdictions | (5) | — |
| Changes in valuation allowances | 2,069 | (1.0) |
Item 16. Form 10-K Summary
FAQ
- What is Wave Life Sciences's GB — effective income tax rate reconciliation tax credits research?
- Wave Life Sciences (WVE) reported GB — effective income tax rate reconciliation tax credits research of 0.2% in Q4 2025.
- What does GB — effective income tax rate reconciliation tax credits research mean?
- This metric measures the percentage point reduction in the effective tax rate resulting from research and development tax credits. It allows investors to evaluate the relative importance of R&D tax incentives in lowering the company's overall tax liability. It is a key indicator of how effectively the company leverages government policy to offset innovation costs.
Ask your AI about Wave Life Sciences's gb — effective income tax rate reconciliation tax credits research.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude